Adaptive Metabolic Disorder Treatments for Specialized Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts a composition for preventing or treating obesity or lipid-related metabolic disorders to address specific challenges in high-altitude environments, disaster relief settings, and areas with limited access to medical care, providing targeted solutions for unique operational environments.
Background and Problem Solved
The original patent disclosed a composition for preventing or treating obesity or lipid-related metabolic disorders, but it did not consider the distinct needs of individuals in specialized environments. This inventive concept addresses the limitations of the original patent by developing adaptive treatments for high-altitude environments, disaster relief settings, and areas with limited access to medical care, where conventional treatments may be ineffective or impractical.
Detailed Description of the Inventive Concept
The inventive concept comprises a system, method, composition, or kit that incorporates a steroid sulfatase inhibitor, such as irosustat, as an active ingredient. The composition is adapted for administration to individuals in high-altitude environments, those with a family history of lipid-related metabolic disease, or those in disaster relief settings. The system may include a remote monitoring device, a communication system, and a portable storage container to facilitate treatment in areas with limited access to medical care. The composition may be formulated in a controlled-release or combination therapy to enhance efficacy and convenience.
Novelty and Inventive Step
The inventive concept's novelty lies in its adaptation of the original composition to address the unique challenges of specialized environments, such as high-altitude environments, disaster relief settings, and areas with limited access to medical care. The inventive step is the recognition of the need for targeted solutions in these environments and the development of compositions, systems, and methods that meet these needs.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include varying the dosage or formulation of the composition, incorporating additional active ingredients, or modifying the system's remote monitoring and communication capabilities. Variations may also include adapting the composition for use in other specialized environments, such as extreme weather conditions or high-security settings.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of metabolic disorder treatment, disaster relief, and remote healthcare. Target markets may include government agencies, non-profit organizations, and private companies operating in specialized environments.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions for metabolic disorders, specifically focusing on steroid sulfatase inhibitors and lipid-related metabolic disease treatments, with expertise in drug formulation, delivery systems, and therapeutic adaptations
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical researcher or clinical pharmacologist with advanced degree, knowledge of metabolic disease treatments, experience in drug delivery systems, and understanding of adaptive pharmaceutical formulations for specialized environments
Obviousness Rationale
A PHOSITA would recognize that adapting the irosustat composition for specialized environments represents a predictable extension of the source patent's core therapeutic approach. The fundamental mechanism of treating metabolic disorders remains consistent, with the variations primarily addressing contextual administration challenges. The PTD's modifications represent routine optimization of drug delivery and application strategies well within the ordinary skill of pharmaceutical researchers.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,533 |
|---|---|
| Title | Composition for preventing or treating obesity or lipid-related metabolic disorders |
| Assignee(s) | Nexyon Biotech Co., Ltd. |